Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does diabetes impact the prognosis of people with colorectal cancer?

2.

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

The need for more Latinx participants in Alzheimer's trials is urgent.

5.

No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot